In clinical practce, we do not recommend the use of mixed tests to screen for antbodies and isotypes, due to their contrastng signifcance and kinetcs. Similarly, we advise against rapid immunochromatographic tests, to avoid diagnostc confusion. CD markers can also be determined using rapid point of care tests. For the tme being, clinicians should be aware that these tests are expensive and they carry the risk of patents startng a GFD themselves, which then makes it harder to confrm the diagnosis.
Finally, it should be noted that ant-transglutaminase antbodies are only of limited use in adults and patents with partal villous atrophy on biopsy.
Introducton
A diagnosis of celiac disease (CD) is reached through an overall assessment of serology, clinical symptoms, intestnal biopsy studies, risk factors and genetc predispositon. Specifc autoantbodies (serological markers) play an essental role in the diagnostc workup. These markers are requested increasingly not only by pediatricians and gastroenterologists, but also by endocrinologists, hematologists, rheumatologists, neurologists and other medical specialists.
Unlike other organ-specifc autoimmune diseases, CD is unique in that it has an identfed trigger (gluten), characteristc infammatory bowel lesion staging that is a reversible, and excellent diagnostc serological markers. It can appear at any age in genetcally susceptble individuals. Positve HLA-DQ2 and/or HLA-DQ8 gluten intake are necessary, but not sufcient for the clinical expression of the disease. Other key aspects are also involved that have yet to be understood, such as molecular mechanisms that control the immune response; mechanisms related to the degree of clinical severity; and the natural history of asymptomatc, untreated CD.
Serological markers are useful for detectng and monitoring CD, but intestnal histology and the response to the gluten-free diet (GFD) establishes the diagnosis. An intestnal biopsy should be requested when there is clinical suspicion and/or positve serology or even when serological tests are negatve in the presence of symptoms suggestve of the disease. The diagnosis is confrmed when there is a clinical, serological and/or histological response to a gluten-free diet (GFD) and it is reinforced by the presence of genetc susceptbility markers HLA-DQ2 or HLA-DQ8.
Serological markers have played a major role in highlightng the heterogeneity of clinical presentatons and they have been used to conduct prevalence studies in the general populaton. They have also made it possible to identfy risk populatons and CD-associated diseases.
History of Serological Markers
Celiac disease was discovered in the 1950s when the Dutch pediatrician, Dicke, 1 identfed a connecton between "intractable diarrhea" and the presence of wheat four in children's diet. Years later it was found that gluten was the antgen that triggered the disease and that intestnal atrophy was reversible.
In 1970, the European Society of Paediatric Gastroenterology and Nutriton (ESPGAN) published the frst diagnostc criteria, 2 consistng of at least three intestnal biopsies: the frst at baseline, the second on a GFD and the third afer a gluten challenge test.
IgA-class antgliadin antbodies (IgA-AGA) were described at the beginning of the 1980s. 3 IgA-AGA was the frst serological marker available for CD, which meant that patents could be screened pre-biopsy, and other clinical forms of CD could be detected in additon to the classical presentaton of diarrhea with abdominal distension. IgA-AGAs are not CD-specifc. They are antbodies to gluten components in the diet, and probably refect increased intestnal permeability, because they are also found in other gut diseases.
The sensitvity and specifcity 4 of the IgA-AGA test is in the range of 70-80%. In clinical practce, lack of sensitvity (the risk of false negatves) causes more harm than the lack of specifcity. The IgA-AGA test gave false negatve results in 10 out of 31 CD cases among frst-degree relatves of patents with CD, 5 and in 4 out of 15 CD cases in a cohort of patents with Down syndrome, 6 all of who had asymptomatc CD. This supports the strong associaton between IgA-AGA and digestve symptoms.
The technical advantages of using IgA-AGA markers in quanttatve immunoassays has meant that they have been widely implemented in CD serological studies and in clinical practce. In fact, they are supplied commercially and form part of the serological marker panels for CD used in some laboratories.
In patents with selectve IgA defciency, IgG markers are determined instead, although IgG-class AGA markers have low specifcity and are very common in the general populaton.
Antendomysial antbodies (EmA) were identfed 7 through their associaton with dermatts herpetformis. The high sensitvity and specifcity of IgA-EmA markers (above 95%) marked a turning point in serological CD detecton. Epidemiological studies that ensued showed high prevalence of CD in the general populaton, and diversity of its clinical forms. The 1970s triple biopsy diagnostc protocol was revised and simplifed by ESPGAN in the 1990s 8 and reduced to a single inital biopsy followed by clinical improvement.
Indirect immunofuorescence (IIF) is used to determine IgA-EmA markers and other antbodies when the antgen is unknown. The immunological reacton takes place on a slide with fxed tssue slices containing the antgen. The most commonly used tssue was monkey distal esophagus. Human umbilical cord (HUC), jejunum (AJA ant-jejunal antbodies) and rat kidney (ARA, antretculin antbodies) have also been used. IIF is a qualitatve or semiquanttatve technique using progressive serum dilutons. It can entail manual or semi-automated processing, and requires well-trained, experienced observers to interpret the paterns under a fuorescent microscope. Monkey distal esophagus slides have a high fnancial and ecological cost. A reasonable alternatve is to use commercially available or in-house-prepared human umbilical cord, although the fuorescent patern is harder to visualize on umbilical cord tssue.
In patents with IgA defciency, IgG-class EmA markers are used, and their microscope image usually shows nonspecifc fuorescence. This makes it harder to interpret an IgG patern than an IgA patern. tTG is an enzyme protein that modifes the indigestble peptdes in dietary gluten in the gut lamina propria, so that they are recognized by HLA-DQ2 molecules and are presented to CD4+ T cells, triggering an infammatory humoral response, with the producton of specifc autoantbodies in patents with CD.
With the tTG antgen now available, EmA can be determined as tTG using quanttatve, automatable immunoassay techniques, thus solving the technical limitatons of IIF.
Quanttatve determinaton of IgA-tTG makes it easier to monitor GFD serology and detects low autoantbody concentratons that cannot be detected using IIF. This is useful in the adult populaton, as explained later in this chapter. Isolated cases of falsely elevated IgA-tTG levels have been reported in patents with acute or serious diseases, 10, 11 as well as small elevatons of IgA-tTG, unrelated to dietary gluten, in patents with autoimmune diseases, 12 but they were considered to be nonspecifc and possibly atributable to impurites in the tTG antgen.
In 2005, scientfc societes 13 recommended IgA-tTG and/or IgA-EmA (with whole IgA) for serum CD detecton; this was the frst tme that the use of IgA-AGA was discouraged.
Ant-deaminated gliadin peptde antbodies (IgA-DGP) have been developed in order to improve the efciency of classical AGA using modifed gliadin peptdes as an antgen, which emulate gluten peptdes in the gut lamina propria. The IgA-DGP test was found to be more efectve than AGA at distnguishing patents with CD from controls in a pediatric populaton. In 2008, the consensus document 16 issued by the Federaton of Internatonal Societes of Pediatric Gastroenterology, Hepatology, and Nutriton did not include the IgA-DGP test in the protocol for CD serological detecton, recommending that its specifcity needed further study.
Children younger than two years with clinically suspected CD may have negatve IgA-tTG but positve IgA-DGP. Analyzing the natural history of IgA-tTG and IgA-DGP in infants, 17 it was observed that IgA-DGP and IgA-tTG markers have diferent kinetcs: IgA-DGPs appear before IgAtTGs and disappear sooner when a GFD is introduced.
In infants, the sensitvity of IgA-DGP contrasts with its lack of specifcity. Thus, IgA-DGP disappeared spontaneously 18 in most children under two years taking gluten who had clinical suspicion of CD and negatve IgA-tTG. In these cases, intestnal biopsy was performed due to clinical suspicion rather than serology results. Another study,
Criteria for Choosing a Commercial Reagent
There is a wide range of commercial tests to determine serological markers in CD. Tests can be grouped by antbody (AGA, EmA, tTG, DGP, mixed DGP/tTG, etc.) isotype (IgA, IgG, IgA/IgG) or technique (IIF, ELISA, fuorescent immunoassay, chemiluminescence assay, etc.)
The choice of test to be used in the clinics should follow internatonal recommendatons and take into account the recent evidence-based literature. Laboratories should choose the most efectve test for the context (adults, children, CD detecton only, detecton and follow-up). Cost should be reasonable, but should not be the only factor in the decision.
Laboratories should be involved in clinicians' decisions to modify or improve CD serology protocols. There must be a good reason for switching tests or adding a new one because this requires an adaptaton period and new reference values.
Serum antbody levels are determined by quanttatve and qualitatve immunoassay techniques, which may be manual or automated. Analyzers are usually connected to an online system. These techniques include ELISA (enzyme-linked immunosorbent assay) with spectrophotometric reading of the fnal result, adaptng signal amplifcaton systems using fuorescence (e.g. fuorescent immunoassay in tTG EIiA™ by Phadia) or luminescence (e.g., chemiluminescence in tTG BiofashR) to increase sensitvity.
The following technical aspects should be taken into account when choosing a test:
• The nature of the antgen(s) in the immunoassay and calibrator type (2, 3 or 6 points).
• The manufacturer's cut-of values.
• Grey or inconclusive zones, if any.
• Sensitvity and specifcity in terms of histology and in the general populaton.
• Imprecision at diferent concentratons (within-run and between-run %CV), partcularly at low concentratons.
• Linearity and detecton limits, and any interferences or other limitatons.
Pack size (e.g., 50 or 500 test pack) and reagent stability should match workload, because a laboratory must be able to ofer a reasonable response tme at a reasonable cost. If the test requires calibraton for each analytcal run, samples should be grouped to reduce calibraton costs. However, if the calibraton is stored in the analyzer memory, individual samples can be determined at no additonal cost. Quality controls must be performed for each analytcal run.
Before introducing a new test, studies must be conducted on imprecision (within-run and between-run %CV) and reproducibility of results using another reference test for the same antbody. In this respect, the lack of a universal calibraton standard is a major drawback, because each manufacturer defnes its own arbitrary standards. . In clinical practce, it is important for the laboratory to identfy this grey zone clearly, and to make sure that the analytcal imprecision for this range is adequate. In order to compare the sensitvity (SENS) and specifcity (SPEC) of diferent representatve serology strategies to detect CD, we used samples that were specifcally selected from our experience of false positve (SENS) and false positve (SPEC) results. We tested 23 serum samples with high IgA-tTG in patents with asymptomatc CD diagnosed by intestnal biopsy (SENS) and 22 serum samples from children aged 1 to 2 years with diarrhea that had resolved with conventonal treatment (SPEC).
The antgens used in the tests were:
1.-Recombinant human tTG (reference test); The test results for each group (see Table 1 ) show that AGA and DGP are indeed less sensitve than tTG for detectng asymptomatc CD. They are also less specifc than tTG in the specially selected group of children with diarrhea resolved with conventonal treatment.
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Marsh III asymptomatc CD n = 23
Children aged 1-2 yeas with diarrhea n = 22
IgA-AGA n=12 n=11 n=3 n=19
IgA-DGP n=17 n=6 n=1 n=21
Screen IgA/IgG tTG/DGP n=23 -n=1 n=21
Ant-neo IgA-tTG bound DGP n=23 -n=2 n=20
IgA-ant-GAF3X n=19 n=4 n=1 n=21
IgG-ant-GAF3X n=17 n=6 n=2 n=20 Mixed tests (used in screening) with more than one antgen (tTG and DGP) and polyvalent conjugates simultaneously detect IgA and IgG class DGP and tTG. They have good sensitvity for CD detecton but they are not useful as a baseline for GFD serological monitoring, because the antbodies and isotypes have diferent kinetcs. Likewise, cauton should be exercised with some commercial tTG tests in which the tTG antgen has been "enriched" with PGD in order to increase sensitvity, as they can give false positve results due to the lack of specifcity of the DGP.
CD markers can also be determined using rapid point of care (POC) tests. Pharmacies can make up these immunochromatographic tests individually to detect IgA and/or IgG tTG and/or DGP using a rapid fngerprick method. They are available as a self-testng kit and provide a quick, inital result for CD that can be carried out at the clinic or at home. The biggest disadvantage is that the test should always be followed up with a conventonal analysis. A positve result needs to be confrmed using the classical diagnostc workup and a negatve result also needs to be investgated if clinical suspicion persists. Furthermore, these tests are expensive and they carry the risk of patents startng a GFD themselves, which then makes it harder to confrm the diagnosis.
Recommendatons for the Use of Serological Markers
Individuals of any age should undergo CD serological screening if they have any unexplained signs or symptoms summarized in Table 2 Individuals consider to belong to risk populatons should also be screened. Risk populatons consist of persons with a higher prevalence of CD than the general populaton, which stands at about 1%. Risk groups of note 22 are frst-degree relatves (10-20%) of CD patents, patents with CD-associated diseases 22 such as type 1 diabetes mellitus (T1DM) (2-12%), Down syndrome (5-12%), autoimmune thyroid disease (up to 7%), Turner syndrome (2-5%), Williams syndrome (up to 9%), selectve IgA defciency (SigAD) (2-8%) and patents with autoimmune liver disease (12-13%).
Serological CD screening is not an urgent procedure in clinical laboratories. CD has a slow onset and it also resolves gradually. Laboratories can therefore return results in a reasonable period ranging from 1 to 7 days, depending on clinics' logistcs and clinicians' expectatons. Results should be assessed in a clinical-dietary-historical context and the head of the laboratory should add comments or contact the clinician, if required. Likewise, the head of the laboratory should play an actve part in selectng the most appropriate markers and most appropriate patents for serological testng, in close coordinaton with the referring clinician. Positve tTG cases should be recorded in a database for future use. According to the latest recommendatons issued by ESPGHAN, 22 IgA-tTG and/or IgA-EmA (if total serum IgA is normal) are the markers of choice for CD, while IgA-DGP markers are recommended as an additonal test in children younger than two years of age with negatve IgA-tTG and suspected CD. Children who are diagnosed before the age of two are candidates for a gluten challenge test, in view of the lack of knowledge of the natural course of gluten intolerance at this early disease stage.
A good clinical laboratory 22 should:
1.-Partcipate in internal and external quality control programs.
2.-Use tests that are validated against an EmA reference standard or histology, with >95% agreement.
3.-Use tests with a manufacturer-defned cut-of or ULN (upper limit of normal) that has been adapted according to personal experience or in view of the populaton studied.
4.-Express results in fgures and specify immunoglobulin class. Classifcaton as "positve" or "negatve" is not sufcient because it does not provide a baseline value for GFD serological monitoring.
5.-Specify the immunoglobulin class and cut-of diluton in EmA reports, indicatng whether the result is positve or negatve, along with the diluton.
6.-Flag negatve IgA-tTG results to avoid misinterpretng cases such as patents with IgA defciency, children younger than two years, patents on a gluten-poor or gluten-free diet (because a few weeks of a GFD will confound a negatve result), and patents receiving immunosuppressive therapy.
Depending on the test, diferent fgures and units of measurements are used for CD serological markers. Reproducibility studies are useful for verifying whether results from such tests are comparable. Results can be expressed as multples of the upper limit of normal (ULN) or with their respectve cut-of values.
Actve collaboraton between clinic and laboratory undoubtedly improves the quality of care. In this respect, it is useful to set up and maintain a database with demographic, clinical, serological, genetc, histological and family data of patents with high IgA-tTG levels as an inital inclusion criterion. Mining this database may help to further our knowledge of CD and improve care protocols.
When laboratories receive a request for "CD serological markers" they should be able to ofer the most appropriate screening tests available. They should not resort to a general panel of antbodies and isotypes that does not provide evidence-based additonal informaton and is simply a burden on human and economic resources.
Serology tests precede histology in all CD diagnostc algorithms. In the latest recommendatons issued by ESPGHAN, 22 the main change is the possibility of diagnosing CD without resortng to intestnal biopsy in children with compatble symptoms, genetc susceptbility and IgA-tTG serum levels >10 tmes the cut-of value or ULN. However, this protocol has been subject to considerable debate, 23, 24 and its opponents suggest that an inital biopsy serves as a reference for the baseline lesion, should the disease develop in an unexpected way, and that it detects discrepancies between serology and histology results. Technical disadvantages include lack of result reproducibility studies on commercial tests, lack of a universal calibraton standard (as mentoned above) and the fact that the positve predictve value (PPV) of IgA-tTG tests depends on CD prevalence in the populaton studied.
The Relatonship between Serology and Histology
Although the level of specifc antbodies in blood is generally understood to refect the degree of intestnal histological lesion, serology and histology results do not always match.
The sensitvity of IgA-tTG/EmA tests is lower in patents with partal villous atrophy. In fact, it has been observed that IgA-tTG/EmA markers may be negatve in 60% of patents with Marsh 3a lesions. 25, 26 Furthermore, negatve IgA-tTG/EmA tests in patents taking a GFD do not necessarily imply histological recovery of villous architecture, especially in adults. 27, 28 Serological response to GFD varies from one patent to another. According to the ESPGHAN, a 12-month GFD is required to achieve a negatve result for CD-specifc antbodies, but this period can range from 3 months to 3 or 4 years, depending on the patent's gluten sensitvity. Likewise, the length of tme required for a gluten challenge test (about 15 g/day in children) to achieve a positve serological result varies greatly. Blood tests should be taken every 3-6 months if there is no clear clinical response. Generally, a positve serological result is sufcient to confrm the diagnosis.
In clinical practce, dietary non-adherence can be detected by serology fndings of some degree of IgA-tTG elevaton in CD patents on a GFD with several previous successive negatve serological controls. This is a common fnding in adolescents and can be atributed to deliberate or accidental non-adherence to their GFD, which they may or may not be aware of. EmA levels determined using IIF assays are less sensitve to these minor serological variatons. IgA-DGP testng is recommended 29 to detect dietary non-adherence, but its lack of specifcity has a negatve impact on the cost-beneft rato.
Serological Markers in Adult CD
Adulthood-onset CD can occur in genetcally susceptble individuals taking dietary gluten. In these cases, elevated IgA-tTG fndings can confrm clinical suspicion before the histological diagnosis is reached. In some cases, late disease onset may be triggered by pregnancy, infectons, trauma or stress, and it can also occur in elderly patents.
Furthermore, CD in adults may go undiagnosed due to the heterogeneity of its signs and symptoms. Serological markers have poor sensitvity because villous atrophy may be partal. An interestng study 30 of consecutve CD diagnoses across all ages showed that CD in adults has atenuated clinical symptoms, serology and intestnal histological lesions compared with CD in children. This means that it takes longer to reach a defnitve diagnosis in adults than in children.
While a low-grade intestnal lesion is associated with mild clinical symptoms, a case-fnding study in relatves of patents with CD 31 proved that clinical symptoms (anemia, abdominal pain or distension or bone density alteratons) are as important in Marsh stage 1 as they are in Marsh stage 3. This study proposed performing an intestnal biopsy in all DQ2-positve relatves of patents with CD, regardless of serological results. The study showed that if a conventonal serological screening protocol had been followed (IgA-tTG and/or IgA-EmA with the standard cutof value), there would have been a 15.6% detecton rate of cases with Marsh 1 lesions and 84.6% detecton rate of cases with Marsh 3 lesions. This confrms the low sensitvity of IgA-tTG markers in adult patents with CD and low-grade intestnal lesions, in whom IgA-tTG elevatons may be below the established cut-of value.
In view of these results and with the aim of increasing IgA-tTG sensitvity in the adult populaton, a new lower cut-of value was sought, based on the IgA-tTG level below which 98% of the general adult populaton belong. 32 This resulted in a cut-of value for adults four tmes lower than the cut-of value for children.
Applying this new cut-of value for adults in a CD case-fnding study in the working populaton, 32 it was found that IgA-tTG had 89% sensitvity and IgA-EmA had 11% sensitvity among patents with Marsh 1 lesions, while both markers had 100% sensitvity for patents with Marsh 3 lesions.
Marsh 1 lesions are not only found in CD; they can also occur in other diseases such Helicobacter pylori infecton, parasite infestaton and other enteropathies. The suitability of the GFD in patents with Marsh 1 lesions in the absence of clinical symptoms is controversial. 33 In these cases, fow cytometry studies in gut mucosa are partcularly relevant because they can detect paterns that are compatble with CD, regardless of histological changes.
Serological Markers in At-Risk Populatons
Serological screening to detect asymptomatc CD in at-risk populatons can be optmized by identfying DQ2 positve cases beforehand. The high negatve predictve value of DQ2 (NPV > 99%) makes it almost impossible to diagnose CD in DQ2-negatve individuals.
However, 64% of frst-degree relatves of patents with CD, 57% of patents with T1DM, 29% of patents with Down syndrome and 25% of the general populaton are DQ2 positve. 34 In consequence, in a DQ2-positve patent with Down syndrome (6% CD prevalence), the probability of positve serology is 1:5, and in a DQ2-positve individual in the general populaton (1% CD prevalence), the probability is 1:25. Therefore, DQ2 is useful to select candidates for serological surveillance in at-risk populatons. In these cases, there are no recommendatons regarding the frequency of performing serological screening in asymptomatc individuals. In the best scenario, these individuals undergo annual serological testng.
IgA-tTG in patents with T1DM
A case-fnding strategy to detect asymptomatc CD in the T1DM populaton consists of IgA-tTG testng when diabetes is diagnosed, and annual serological monitoring thereafer. With this strategy, 35 CD was diagnosed in 6.4% (13 out of 202) patents who had newly-diagnosed T1DM, during 6 consecutve years of systematc screening. According to the same study, CD has a strong associaton with early-onset T1DM and there is no preferental order of appearance between the two diseases. This is corroborated by asymptomatc CD being detected by serology at the tme of the diabetes diagnosis in half the cases, whereas it was detected during serological monitoring during the next three years in the other half of cases. Inconclusive or weak positve CD serology at the onset of diabetes should be interpreted with cauton, and developments should be monitored.
IgA-tTG in patents with IgA Defciency
CD is associated with selectve IgA defciency. Serum IgA defciency (serum IgA < 10 mg/L) is the most common of primary immunodefciency diseases and it afects 0.2% of the general populaton. It is usually asymptomatc.
If selectve IgA defciency is found by chance, IgG-class tTG markers should be systematcally tested. Following this strategy, Analyzing the serology fndings in this populaton, 37 it was found that IgA defciency was absolute in 70% of cases and that only class IgG tTG antbodies were detected. The remaining 30%, however, accounted for partal or transient IgA defciency, and tTG antbodies of IgA and IgG classes were detected in 80% of cases.
Since IgG antbodies have a longer half-life than IgA antbodies, they take longer to disappear in GFD monitoring. Thus, IgG-tTG tests are stll positve afer 2 to 11 years of GFD, while IgA-tTG tests are negatve afer 1 to 4 years of GFD in 100% of cases.
Serological Markers in the General Populaton
CD is a common disease. It may remain undiagnosed because of the heterogeneity of clinical presentatons. It has excellent diagnostc serological markers. It has efectve treatment without side efects and lack of treatment is associated with negatve efects.
In view of the above, CD appears to be an ideal disease to study in the general populaton. 38, 39 However, there are drawbacks to conductng a massive study of CD in the general populaton such as lack of knowledge of the natural history of asymptomatc, untreated CD; lack of motvaton for asymptomatc patents to adhere to a GFD; CD onset at any age, which would require repeated serological screening; and lack of cost-beneft studies.
For the same reasons, it is not recommended to add IgA-tTG screening to routne tests in healthy general populaton groups, such as medical check-ups at work, blood donors and pre-operatve checklists for minor surgery. However, if there is an accidental fnding of microcytc anemia or a slight elevaton of ALT levels in blood 40 in routne tests, then systematc IgA-tTG determinaton would facilitate asymptomatc CD detecton. Unexplained anemia or elevated transaminases are known extradigestve manifestatons of asymptomatc CD.
It is accepted that CD prevalence in the general populaton is approximately 1:100. However, it is stll widely held that CD is more prevalent in children. Epidemiological studies conducted in diferent age groups in the Spanish populaton show that prevalence ranges from 1:118 in children younger than 3 years 41 to 1:220 in primary school children 42 , and 1:389 in the general populaton 43 with a mean age of 35 years. This apparent decreasing prevalence as age increases has recently been confrmed in an epidemiological study 44 of 4230 persons aged 1 to 90 years in the general populaton in Catalonia. The results from this study show that CD is 5 tmes more common in children than in adults, and that this increase is largely due to prevalence in the youngest children. This age-related fall in prevalence is hard to explain in view of the fact that CD is a permanent, non-resolving disease. The hypothesis of spontaneous progress to a latent state can only be investgated through longitudinal natural history studies.
